Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 195

1.

[Chronic neutrophilic leukemia: a long-term analysis of seven cases and review of the literature].

Telek B, Batár P, Udvardy M, László R.

Orv Hetil. 2006 May 7;147(18):827-30. Hungarian.

PMID:
16784137
2.

Efficacy of imatinib mesylate (STI571) in chronic neutrophilic leukemia with t(15;19): case report.

Choi IK, Kim BS, Lee KA, Ryu S, Seo HY, Sul H, Choi JG, Sung HJ, Park KH, Yoon SY, Oh SC, Seo JH, Choi CW, Shin SW, Yoon SY, Cho Y, Kim YK, Kim YH, Kim JS.

Am J Hematol. 2004 Dec;77(4):366-9.

3.

Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up.

Palandri F, Castagnetti F, Testoni N, Luatti S, Marzocchi G, Bassi S, Breccia M, Alimena G, Pungolino E, Rege-Cambrin G, Varaldo R, Miglino M, Specchia G, Zuffa E, Ferrara F, Bocchia M, Saglio G, Pane F, Alberti D, Martinelli G, Baccarani M, Rosti G; GIMEMA Working Party on Chronic Myeloid Leukemia.

Haematologica. 2008 Dec;93(12):1792-6. doi: 10.3324/haematol.13068. Epub 2008 Oct 6.

4.

Transition of polycythemia vera to chronic neutrophilic leukemia.

Higuchi T, Oba R, Endo M, Harada H, Mori H, Niikura H, Omine M, Fujita K.

Leuk Lymphoma. 1999 Mar;33(1-2):203-6. Review.

PMID:
10194140
5.

[A case of chronic neutrophilic leukemia accompanied with severe bone marrow fibrosis which was effectively treated by hydroxyurea].

Hirayama Y, Koda K, Matsumoto S, Takayanagi M, Ezoe A, Nobuoka A, Nakazawa O.

Rinsho Ketsueki. 1994 Nov;35(11):1329-34. Japanese.

PMID:
7823400
7.
8.

Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near-complete cytogenetic response to interferon-alpha.

Branford S, Hughes T, Milner A, Koelmeyer R, Schwarer A, Arthur C, Filshie R, Moreton S, Lynch K, Taylor K.

Cancer. 2007 Aug 15;110(4):801-8.

9.

Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome.

Palandri F, Iacobucci I, Castagnetti F, Testoni N, Poerio A, Amabile M, Breccia M, Intermesoli T, Iuliano F, Rege-Cambrin G, Tiribelli M, Miglino M, Pane F, Saglio G, Martinelli G, Rosti G, Baccarani M; GIMEMA Working Party on CML.

Haematologica. 2008 May;93(5):770-4. doi: 10.3324/haematol.12265. Epub 2008 Mar 26.

10.

Intermittent dosage of imatinib mesylate in CML patients with a history of significant hematologic toxicity after standard dosing.

Faber E, Nausová J, Jarosová M, Egorin MJ, Holzerová M, Rozmanová S, Maresová I, Divoký V, Indrák K.

Leuk Lymphoma. 2006 Jun;47(6):1082-90.

PMID:
16840200
11.

Dose modification of imatinib by monitoring the level of BCR-ABL transcript in chronic myelogenous leukemia.

Ishikawa I, Kato C, Harigae H, Sugawara T, Tomiya Y, Yamada M, Ishizawa K, Kameoka J, Miyamura K, Sasaki T.

Tohoku J Exp Med. 2006 Dec;210(4):355-63.

12.

Chronic neutrophilic leukemia: a contemporary review.

Elliott MA.

Curr Hematol Rep. 2004 May;3(3):210-7. Review.

PMID:
15087070
13.

Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenic response after interferon-alpha results in a very high complete molecular response rate.

Alimena G, Breccia M, Luciano L, Quarantelli F, Diverio D, Izzo B, De Angelis B, Mancini M, Latagliata R, Carmosino I, Nanni M, Picardi M, Rotoli B, Mandelli F, Pane F.

Leuk Res. 2008 Feb;32(2):255-61. Epub 2007 Aug 10.

PMID:
17692911
14.

Imatinib activity in vitro in tumor cells from patients with chronic myeloid leukemia in chronic phase and blast crisis.

Olsson-Strömberg U, Aleskog A, Björnberg A, Höglund M, Simonsson B, Bengtsson M, Barbany G, Larsson R, Lindhagen E.

Anticancer Drugs. 2006 Jul;17(6):631-9.

PMID:
16917208
15.

Coexistence of chronic neutrophilic leukemia with multiple myeloma.

Dinçol G, Nalçaci M, Doğan O, Aktan M, Küçükkaya R, Ağan M, Dinçol K.

Leuk Lymphoma. 2002 Mar;43(3):649-51. Review.

PMID:
12002774
16.

Chronic myeloid leukaemia and hairy cell leukaemia coexisting in a single patient: difficulties at diagnosis and rational of the therapeutic strategy.

Orciuolo E, Fazzi R, Galimberti S, Testi C, Azzara' A, Carulli G, Petrini M.

Leuk Res. 2006 Mar;30(3):349-53. Epub 2005 Sep 21.

PMID:
16182365
17.

[Chronic neutrophilic leukemia: apropos of 2 cases and review of the literature].

Hidalgo C, Camacho J, Fernández J, Hernández A, Poveda F, Peña JM.

Med Clin (Barc). 1990 Oct 6;95(11):421-3. Spanish.

PMID:
2082113
18.

Successful interim therapy with imatinib prior to allogeneic stem cell transplantation in Philadelphia chromosome-positive acute myeloid leukemia.

Cho BS, Kim HJ, Lee S, Eom KS, Min WS, Lee JW, Kim CC.

Eur J Haematol. 2007 Aug;79(2):170-3. Epub 2007 Jun 28.

PMID:
17608710
19.

Long-term remission with imatinib mesylate in Philadelphia chromosome-positive AML presenting as primary extramedullary myeloid sarcoma.

Ahmed MS, Kroft SH, Davis NB, King DM, Cheng YC.

Leuk Res. 2008 Sep;32(9):1476-9. doi: 10.1016/j.leukres.2008.01.012. Epub 2008 Mar 4.

PMID:
18308388
20.

Is it possible to discontinue imatinib mesylate therapy in Chronic Myeloid Leukemia patients with undetectable BCR/ABL? A case report and a review of the literature.

Guastafierro S, Falcone U, Celentano M, Coppola M, Ferrara MG, Sica A.

Leuk Res. 2009 Aug;33(8):1079-81. doi: 10.1016/j.leukres.2008.11.027. Epub 2009 Jan 22. Review.

PMID:
19167064

Supplemental Content

Support Center